School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
Bostal Durg Delivery Co., Ltd., Guangzhou 510320, China.
Curr Pharm Des. 2024;30(32):2574-2585. doi: 10.2174/0113816128295265240613061905.
Essential hypertension is a common clinical disease and a risk factor for cardiovascular and cerebrovascular diseases. Olmesartan medoxomil, amlodipine, and hydrochlorothiazide are commonly used antihypertensive drugs. The aim of this study was to establish a robust UPLC-MS/MS method for the simultaneous determination of olmesartan medoxomil, amlodipine, and hydrochlorothiazide in dog plasma. At the same time, the and release studies were conducted, and a preliminary correlation (IVIVC) evaluation was performed.
The bioequivalence experiment was conducted with a double-crossed design. Three major components were extracted and analyzed by UHPLC-MS/MS. With the MRM scan, olmesartan and amlodipine were quantified by fragment conversion (m/z 447.10→190.10) and (m/z 408.95→294.00) under positive ESI mode, while hydrochlorothiazide was quantified with fragment conversion (m/z 295.90→268.90) under negative ESI mode. The release studies were performed using a USP paddle, and the dissolution medium was chosen from pH 6.0 to pH 6.8 according to the BCS classification of compounds. The IVIVC was calculated using the Wagner-Nelson equation.
The linear ranges of olmesartan, amlodipine, and hydrochlorothiazide in the plasma were 5.0-2500, 0.1-50, and 3.0-1500 ng/mL, respectively. All accuracies were within 3.8% of the target values, and the findings revealed that intra-day and inter-day accuracies were less than 12.1%. Moreover, the recoveries exceeded 88.3%, the matrix effect tests were positive, and the stability tests were positive. With the establishment of correlation, the distinguishable dissolution condition (pH 6.8) was selected as the predictable condition.
The established method was suitable for the preclinical pharmacokinetic study of tripartite drugs with strong specificity and high sensitivity. Through the evaluation of IVIVC, the connection between in vivo and drug testing was initially established.
原发性高血压是一种常见的临床疾病,也是心血管和脑血管疾病的危险因素。奥美沙坦酯、氨氯地平、氢氯噻嗪是常用的降压药物。本研究旨在建立一种同时测定犬血浆中奥美沙坦酯、氨氯地平和氢氯噻嗪的稳健 UPLC-MS/MS 方法。同时进行了 和释放研究,并进行了初步的体内外相关性(IVIVC)评价。
采用双交叉设计进行生物等效性实验。采用 UHPLC-MS/MS 提取和分析三种主要成分。采用正离子电喷雾模式下的碎片转换(m/z 447.10→190.10)和(m/z 408.95→294.00)对奥美沙坦和氨氯地平进行定量,负离子电喷雾模式下的碎片转换(m/z 295.90→268.90)对氢氯噻嗪进行定量。采用 USP 桨法进行 释放研究,根据化合物的 BCS 分类选择 pH 6.0 至 pH 6.8 的溶解介质。采用 Wagner-Nelson 方程计算 IVIVC。
奥美沙坦、氨氯地平和氢氯噻嗪在血浆中的线性范围分别为 5.0-2500、0.1-50 和 3.0-1500ng/mL。所有准确度均在目标值的 3.8%以内,日内和日间准确度均小于 12.1%。此外,回收率超过 88.3%,基质效应试验阳性,稳定性试验阳性。建立相关性后,选择可区分的溶解条件(pH 6.8)作为可预测条件。
所建立的方法适用于三方药物的临床前药代动力学研究,具有较强的特异性和较高的灵敏度。通过 IVIVC 的评价,初步建立了体内和 药物检测之间的联系。